BioCryst, HHS extend peramivir agreement for 31 days BioCryst Pharmaceuticals disclosed that it and the U.S. Department of Health and Human Services mutually agreed to extend their agreementís current expiration date of February 28 for 31 days. The new expiration date is changed to March 31. The extension of the agreement will allow ongoing stability testing of peramivir to continue beyond the current contract expiration date. All other terms and conditions of the agreement remain unchanged.
BioCryst upgraded to Buy on BCX7353 potential at BofA/Merrill As previously reported, BofA/Merrill upgraded BioCryst to Buy from Neutral and increased its price target to $19 from $12. The firm raised the probability of BCX7353 approval to 40% from 25% given validation of the plasma kallikrein target by both Ď4161 and competitor product and now assign a $13/share value versus near zero previously. BofA/Merrill is now assigning a modest negative value for '4161 versus approximately $7/share previously.